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Abstract
Background: Recent evidence links aberrant activation of Hedgehog (Hh) signaling with the pathogenesis of several cancers
including medulloblastoma, basal cell, small cell lung, pancreatic, prostate and ovarian. This investigation was designed to
determine if inhibition of this pathway could inhibit serous ovarian cancer growth.
Methodology: We utilized an in vivo pre-clinical model of serous ovarian cancer to characterize the anti-tumor activity of Hh
pathway inhibitors cyclopamine and a clinically applicable derivative, IPI-926. Primary human serous ovarian tumor tissue
was used to generate tumor xenografts in mice that were subsequently treated with cyclopamine or IPI-926.
Principal Findings: Both compounds demonstrated significant anti-tumor activity as single agents. When IPI-926 was used
in combination with paclitaxel and carboplatinum (T/C), no synergistic effect was observed, though sustained treatment
with IPI-926 after cessation of T/C continued to suppress tumor growth. Hh pathway activity was analyzed by RT-PCR to
assess changes in Gli1 transcript levels. A single dose of IPI-926 inhibited mouse stromal Gli1 transcript levels at 24 hours
with unchanged human intra-tumor Gli1 levels. Chronic IPI-926 therapy for 21 days, however, inhibited Hh signaling in both
mouse stromal and human tumor cells. Expression data from the micro-dissected stroma in human serous ovarian tumors
confirmed the presence of Gli1 transcript and a significant association between elevated Gli1 transcript levels and worsened
survival.
Conclusions/Significance: IPI-926 treatment inhibits serous tumor growth suggesting the Hh signaling pathway contributes
to the pathogenesis of ovarian cancer and may hold promise as a novel therapeutic target, especially in the maintenance
setting.
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Introduction
In the United States, ovarian cancer is estimated to afflict
approximately 22,000 women and cause nearly 14,000 deaths
annually. The lifetime risk of developing ovarian cancer is 1 in 70
and it is the fifth most lethal cancer in women [1]. Most ovarian
cancer patients present with late-stage disease that is treated with
surgical debulking and platinum based chemotherapy. Although
70–80% of women achieve a complete clinical response, a
majority of those patients will develop recurrent disease that is
frequently chemoresistant. Novel treatment approaches utilizing
conventional cytotoxic therapies in combination with molecularly
targeted therapies directed against specific signaling pathways
required for tumor development and progression potentially hold
promise as strategies for durable treatment of primary and
recurrent ovarian cancer [2].
The Hedgehog (Hh) signal transduction pathway comprises a
family of highly conserved proteins that primarily act during
embryogenesis to regulate stem cell fate and organogenesis, and
promote proliferation, regeneration and differentiation of somatic
tissues in the adult [3]. Patched 1 (Ptch1), a membrane receptor,
normally inhibits the membrane protein Smoothened (Smo) from
activating Gli1. The binding of Hh ligand (Sonic, Indian or
Desert) to Ptch1 abrogates its repressive effects on SMO allowing
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expression of target genes [4,5]. Aberrant activation of the Hh
pathway in adulthood has been associated with the development of
malignant transformation in a variety of human cancers
[4,6,7,8,9,10,11,12]. Additionally, tumor initiating cells in some
cancers have been shown to be dependent on sustained Hh
induced signaling and subsequent activation of Gli1 resulting from
ligand over-expression or mutational activation of the Hh pathway
[6,13]. Treatment regimens with Hh pathway antagonists in
combination with conventional molecular and cytotoxic therapies
have demonstrated in vitro and in vivo activity against proliferation
in medulloblastoma, basal cell, breast, small cell lung, prostate and
pancreatic cancer models [10,11,12,14,15,16,17]. These antago-
nists are currently in Phase I and Phase II clinical trials.
Activation of the Hh pathway has been documented in ovarian
cancer as a potential mechanism involved in neoplasia. Altered
gene and protein expression of the Hh pathway members Gli1,
Smo, Ptch1, Desert hedgehog (Dhh) and Sonic hedgehog (Shh) in
ovarian cancer has been reported, although the exact prevalence
and pattern remains to be clarified [18,19,20,21]. While many
studies suggest that 50–60% of invasive ovarian tumors manifest
Hh pathway activation, other investigators have argued that
meaningful activation via altered expression of multiple pathway
proteins occurs in less than 20% of clinical samples tested [19,20].
While a direct correlation between the expression of Dhh and
clinical stage, histologic subtype or survival has been reported, it is
currently unclear whether expression of the Dhh ligand is
associated with decreased survival [20]. Other analyses of ovarian
carcinoma samples have suggested that elevated Gli1 protein
expression is an independent factor associated with decreased
survival when adjusting for age, stage, grade and histologic type
[18].
In vitro and limited in vivo studies provide evidence to suggest that
Hh signaling pathway plays an important role in ovarian cancer
cell proliferation. Shh was detected in a number of ovarian cancer
cell lines and addition of a monoclonal antibody against Shh
resulted in a dose dependent decrease in cell proliferation [21].
Similarly, treatment of cultured ovarian cancer cells with the Smo
inhibitor cyclopamine has been found to induce cell cycle arrest in
G1 and promote apoptosis [20]. Moreover, ectopic expression of
Gli1 in ovarian cancer cells resulted in increased cell proliferation,
mobility and invasive properties [18]. Ovarian carcinoma cell line
derived xenografts are also susceptible to Hh pathway inhibition as
their growth is markedly impaired following treatment with
cyclopamine [21]. The majority of available data suggest that an
activated Hh signaling cascade may be a potential driver of
neoplasia in a significant proportion of epithelial ovarian cancers
making it an attractive target for therapeutic inhibition.
We have explored this possibility using the Hh pathway
inhibitor IPI-926, a derivative of cyclopamine with increased oral
bioavailability and a longer half-life [22]. IPI-926 antagonizes the
Hh pathway by inhibiting Smo. IPI-926 induces a dose dependent
reduction in Gli1 mRNA expression and durable tumor remission
in a murine medulloblastoma model [22]. Although IPI-926 had
no effect as a single agent in a mouse model of small cell lung
cancer prior to chemotherapy, animals treated with IPI-926
following chemotherapy exhibited a dramatic inhibition in tumor
re-growth [22]. Given these pre-clinical data, we sought to
determine whether inhibition of the Hh pathway by cyclopamine
or IPI-926 had an effect on the growth of human papillary serous
ovarian cancer xenografts derived from primary human tissue
obtained at the time of initial surgery. We then assessed the anti-
tumor activity of IPI-926 in our xenograft model in combination
with paclitaxel and carboplatinum and as a single agent
maintenance therapy. Finally, the effect of a single dose and
prolonged IPI-926 treatment on Hh pathway activity was
determined in both the stromal and tumor cell populations. Our
results support the hypothesis that the Hh signaling pathway
contributes to the pathogenesis of serous ovarian cancer and
inhibition of this pathway may have therapeutic benefit.
Materials and Methods
Immunohistochemical analysis
An ovarian cancer tissue microarray (T8235725, Biochain,
Hayward, CA) comprising 64 benign and malignant ovarian
human tumors was used for immunohistochemical analysis of Shh
protein expression. Antigen retrieval was carried out in citrate
target retrieval buffer using a pressure cooker for 40 minutes and
the sections were treated with 3% hydrogen peroxide and
incubated in Background Sniper (Biocare, Concord, CA) to block
any non-specific binding. Incubation of the sections with the anti-
Shh monoclonal antibody ab53281 (Abcam, Cambridge, MA)
diluted 1:2000 in DaVinci Green diluent (Biocare Medical,
Concord, CA) was carried out at room temperature for
90 minutes. The sections were then incubated with rabbit on
rodent polymer system (Biocare Medical, Concord, CA) for
45 minutes at room temperature. Slides were then treated with 3,
39-diaminobenzidine chromagen (DAB) for 5 minutes for visual-
ization. Sections were then counterstained with hematoxylin,
dehydrated and mounted. Total rabbit IgG substituted for the
primary antibodies served as a negative control.
Tumor collection and propagation in vivo
Excess human tumor or ascites samples were obtained through
an IRB approved centralized banking infrastructure at the
Massachusetts General Hospital (MGH). Written informed
consent is received from all participants. There were no samples
derived from minors in this study. The MGH Gyn tissue
repository protocol (07-049) was reviewed and approved by the
Dana-Farber Harvard Cancer Center (DFHCC). In addition, we
utilized archived samples derived from MGH pathology under an
institutional approved protocol (2008P001695).
Single cell suspensions from either enzymatically processed solid
tumor tissue or ascites were then depleted of hematologic
components as described [23]. A specified number of cells were
suspended in PBS:MatrigelH (1:1) and injected subcutaneously
(s.c.) into 6–8 week old female NOD/SCID mice (Jackson
Laboratory, Bar Harbor, ME). Animals were monitored regularly
to determine tumor formation and euthanized when they became
moribund or had excessive tumor burden. All animal experiments
were conducted in strict accordance with the recommendations in
the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. The protocol was approved by the
Massachusetts General Hospital Sub-Committee on Research and
Animal Care (protocol number 2005N000273). Every effort was
made to minimize suffering.
For continued propagation in mice, the xenograft tumors were
excised and enzymatically processed to a single cell suspension.
The suspension was depleted of mouse H-2K
d+ cells using MACS
beads (Miltenyi Biotech, Bergisch Gladbach, Germany) and the
remaining tumor-derived cells were re-injected subcutaneously
into new recipient NOD/SCID mice. All of the primary human
papillary serous ovarian tumors utilized in this study had
undergone 4–5 passages in vivo and the serous histology of each
was maintained over the serial transplantation process. Animals
were housed and maintained in accordance with institutional
guidelines.
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Cyclopamine. Mice bearing matched sized tumors (300–
600 mm
3) from the human serous ovarian cancer sample SOC11
were randomized into two groups of six mice. Each cohort
received either 25 mg/kg cyclopamine or vehicle (30% (w/v) 2-
hydroxypropyl-b-cyclodextrin (HPBCD) in 0.1 M sodium citrate
phosphate buffer, pH 3.0) by daily oral gavage. The treatment
period spanned 13 days. Tumor measurements and animal
weights were assessed every 4 days. Tumors were measured
weekly with calipers and tumor volume (mm
3) was determined
using the formula [length (mm)6width (mm)6width (mm)]/2.
Mouse weights were assessed every 4–7 days to monitor potential
toxicity associated with each treatment. At the end of the
treatment period the animals were euthanized and the tumors
were harvested for further analysis.
IPI-926: Twenty-four mice bearing SOC12, SOC13 or SOC14
xenograft tumors were randomized into four cohorts with matched
tumor volumes (300–600 mm
3). The paclitaxel/carboplatinum
(T/C) alone cohort received weekly intraperitoneal (i.p.) injection
of 15 mg/kg paclitaxel and 50 mg/kg carboplatinum and the IPI-
926 vehicle 5% (w/v) (HPBCD) administered every other day by
oral gavage. The IPI-926 alone cohort received 40 mg/kg IPI-926
every other day by oral gavage and Cremophor:ethanol (1:1,
paclitaxel vehicle) and saline (carboplatinum vehicle) by weekly i.p.
injection. Mice in the T/C+IPI-926 cohort received weekly
paclitaxel (15 mg/kg, i.p.) and carboplatinum (50 mg/kg, i.p.) and
40 mg/kg IPI-926 (every other day, oral gavage). The control
cohort received the paclitaxel, carboplatinum and IPI-926 vehicles
at the dosing schedule appropriate for each. Tumor volumes and
mouse weights were assessed every 4–7 days as described above.
The last dose in the T/C cohort was administered on day 14.
After 21 days, mice in the control and IPI-926 alone cohorts were
euthanized and their tumors were harvested. Portions of each
tumor were snap frozen for RNA analysis and embedded in
paraffin for histological analysis.
Following the completion of T/C treatment, mice in the T/C
alone and T/C+IPI-926 cohorts continued to receive either IPI-
926 vehicle (T/C alone group) or 40 mg/kg IPI-926 (T/C+IPI-
926 group) every other day by oral gavage. This maintenance
treatment was carried out for 18–30 days. At the end of the
maintenance period, animals were euthanized and tumors were
harvested and processed for RNA and histological analyses as
described above.
Acute IPI-926 treatment
Mice harboring xenografts (300–600 m
3) derived from SOC12,
SOC13 or SOC14 were treated with either 40 mg/kg IPI-926 or
IPI-926 vehicle by oral gavage. After 24 hours the animals were
euthanized. Their tumors were harvested and portions of each
were snap frozen for RNA analysis and embedded in paraffin.
RT-PCR analysis
RNA was isolated from frozen tumor tissue using the
GenElute
TM mammalian RNA extraction kit (Sigma Aldrich, St.
Louis, MO) following the manufacturer’s instructions. Two
micrograms of isolated RNA were used to synthesize cDNA using
the Invitrogen Superscript
TM VILO kit (Invitrogen, Carlsbad,
CA). Primers and probes for mouse Gli1 were purchased from
Applied Biosystems Inc. (Carlsbad, CA, catalog number
Mm00494645_m1). Primers and probes for human Gli1 were
designed in-house: forward: 59-CTTTCATCAACTCGCGA-
TGC-39; reverse: 59-GCTCATGGTGCCAATGGAG-39; probe:
59FAM-CATCTCCAGGAGGCTCCTACGGTCA TC- TAM-
RA-39. Primers were designed to span exon-exon junctions to
prevent detection of genomic DNA. The expression levels of the
human and mouse Gli1 genes were normalized to GAPDH and
quantified as described by Applied Biosystems Inc.
In addition to Gli1 mRNA, we analyzed SHH, SMO, and Ptch1
mRNA levels in the 4 patient samples used to generate tumor
explants for testing the inhibition of the Hhog pathway. Primers
and probes for human SHH (catalog number Hs00179843_m1),
SMO (catalog number Hs00170665_m1), and Ptch1 (catalog
number Hs00970980_m1) were purchased from Applied Biosys-
tems Inc. (Carlsbad, CA).
The expression levels of the human SHH, SMO, and Ptch1 genes
were normalized to GAPDH and quantified as described by
Applied Biosystems Inc.
Analysis of Gli1 expression in human ovarian tumor
stroma
High-grade late-stage serous primary ovarian tumors specimens
were obtained prior to chemotherapy from 19 ovarian cancer
patients hospitalized at the Brigham and Women’s Hospital
between 1990 and 2000. Classification was determined according
to the International Federation of Gynecology and Obstetrics
standards. All specimens and their corresponding clinical infor-
mation were obtained under IRB-approved protocols. Microdis-
section and RNA isolation were performed as previously described
[24]. Briefly, fibroblasts from 7 mm frozen sections were
microdissected using a MD LMD laser microdissecting micro-
scope (Leica, Wetzlar, Germany) and lysed in RLT lysis buffer
(Qiagen, Valencia, CA). RNA was extracted and purified using the
RNeasy Micro kit (Qiagen, Valencia, CA). Total RNA specimens
were quantified and checked for quality with a Bioanalyzer 2100
system (Agilent, Palo Alto, CA) and then amplified as previously
described [24]. Quantitative real-time PCR (qRT-PCR) was
performed on 50 ng of double-amplified product from the 19
specimens using primer sets specific for Gli1 (forward AC-
CCCCTGGACTCTCTTGAT, reverse GACACTCATGTTG-
CCCACAG). An iCycler iQ Real-time PCR Detection System
(Bio-Rad Laboratories, Hercules, CA) was used in conjunction
with the SuperScript III Platinum SYBR Green One-Step qRT-
PCR kit (Invitrogen, Carlsbad, CA) according to the manufactur-
er’s instructions.
Statistical Analysis
Non-parametric Wilcoxan rank sum tests for unpaired samples
were used to compare tumor sizes in the cyclopamine and IPI-926
treatment experiments. Student’s t-tests were used to determine
the statistical significance of results obtained in the IPI-926 acute
and prolonged treatment experiment. Significance was set at
p#0.05. STATA (College Station, TX) v10 software was used.
The survival analysis was performed using GraphPad Prism
version 5.00 for Windows (GraphPad Software, San Diego
California USA).
Results
Shh and Gli1 expression in human ovarian tumors
Recent studies have highlighted the role of the Hh signaling
pathway in development and progression of solid tumors [25]. We
assessed the relative expression of the Hh pathway members Shh
and Gli1 in a subset of ovarian tumors. As shown in Figure 1A,
immuohistochemical analysis of Shh expression on a tissue
microarray comprising benign and malignant tumors determined
that 47% of the evaluated malignant epithelial ovarian tumors had
detectable levels of Shh expression. In comparison, Shh expression
was detected in only 1 of 5 non-epithelial ovarian tumors. As
Hedgehog Inhibition Blocks Ovarian Tumor Growth
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distribution of Shh expression varied widely across the analyzed
tumors. We then examined the expression of Gli1 mRNA in the
individual primary human papillary serous ovarian tumors SOC1-
SOC10 (see Table S1 for patient details) by RT-PCR. We
observed a wide range of Gli1 mRNA expression across the
analyzed tumors (Figure 1B). In addition, we analyzed SHH, SMO,
Ptch1, and Gli1 mRNA levels in the 4 individual patient samples we
used to generate tumor xenografts for analyzing the effect of Hh
pathway inhibition on ovarian tumor growth in vivo (Figure 2). In
each of the tumors, Gli1 and SMO were more abundantly
expressed relative to Ptch1. There was little to no SHH mRNA
Figure 1. Sonic hedgehog (Shh) and Gli1 are variably expressed in human ovarian tumors. A. Immunohistochemical analysis of Shh
expression was carried out on a tissue microarray carrying 64 individual primary ovarian tumors to assess both the frequency and level of Shh
expression in human ovarian cancer. The Shh staining in a poorly differentiated serous cystadenocarcinoma (upper left panel), a poorly differentiated
mucinous cystadenocarcinoma (upper right panel), a well-differentiated cystadenocarcinoma (lower left panel), and a poorly differentiated
adenocarcinoma (lower right panel) is shown. The table summarizes the frequency of Shh staining in the benign tumors and non-epithelial and
epithelial malignancies present in the ovarian tumor microarray. B. Real-time Q-PCR was performed for analysis of Gli1 mRNA levels in 10 primary
human papillary serous ovarian cancer tumors. Primers specific for human Gli1 and GAPDH were used. For each sample, the level of Gli1 mRNA
relative to the level of GAPDH mRNA is shown.
doi:10.1371/journal.pone.0028077.g001
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analyses suggest that the Hh signaling pathway is activated in a
subset of human ovarian tumors as previously reported.
Inhibition of Hh signaling blocks the growth of human
serous ovarian tumor xenografts
To assess the functional significance of the Hh pathway in the
progression of ovarian cancer, we treated mice harboring human
serous ovarian tumor xenografts generated from the platinum
sensitive tumor SOC11 with either the Hh pathway inhibitor
cyclopamine or vehicle and regularly assessed the effect of each
treatment on tumor volume. In the cyclopamine-treated mice,
tumor growth was precluded over the thirteen-day treatment
period resulting in a significantly (p,0.004) decreased tumor
volume at day 13 relative to that observed in the vehicle treated
animals (Figure 3). Minimal toxicity was observed in cyclopamine
treated animals with no observed statistically different changes in
mouse weight (Figure S1).
Our analysis of cyclopamine effect on tumor xenograft growth
suggested that inhibition of Hh signaling may be an effective
approach to controlling ovarian tumor progression. We next
carried out similar experiments using the more chemically potent
and clinically applicable Hh pathway inhibitor IPI-926 currently
in Phase I/II clinical trials in non-ovarian solid tumors. IPI-926 is
derived from cyclopamine and has improved pharmaceutical
properties including higher potency, a longer half-life and
increased bioavailability. We were especially interested in
examining the potential utility of IPI-926 in combination with
Figure 2. Hedgehog pathway components are differentially expressed in primary human ovarian tumors. The expression of Gli1, Ptch1,
SHH and SMO was analyzed by RT-qPCR in 4 primary human serous ovarian tumors (SOC11-SOC14) established as xenografts in NOD/SCID mice.
Primers specific for each human gene and human GADPH were used. For each tumor, the levels of each gene relative to GADPH mRNA are shown.
doi:10.1371/journal.pone.0028077.g002
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experiments utilizing independent primary human serous ovarian
xenograft tumors (SOC12, SOC13, and SOC14) to analyze the
anti-tumor activity of IPI-926 alone or in combination with
paclitaxel and carboplatinum (T/C). The tumor xenografts were
derived from 2 patients with platinum resistant disease (SOC12,
SOC13) and 1 patient with platinum sensitive disease (SOC14)
and the results of those analyses are shown in Figure 4. Mice
bearing primary human serous ovarian tumor xenografts were
randomized into four treatment groups which received either
vehicle control, IPI-926 alone, T/C alone or IPI-926 and T/C.
Over the initial treatment period (days 0–21), tumor volume in
mice treated with the vehicle control increased dramatically
(Figures 4A, 4B, 4C). Treatment of SOC12, SOC13 and SOC14
xenografts with T/C alone resulted in a significant decrease in
tumor volume (p,0.05; p,0.007; p,0.001 respectively) relative
to the control treatment. Like cyclopamine, IPI-926 as a single
agent had a statistically significant inhibitory effect on tumor
growth relative to vehicle control for both SOC13 (Figure 4B,
p,0.007) and SOC14 (Figure 4C, p,0.01). The combination of
IPI-926 and T/C demonstrated no greater anti-tumor activity
than T/C alone for all tested tumors. In these analyses, we
observed no significant weight loss in animals treated with IPI-926
as a single agent compared to vehicle treated animals (Figure S2).
We next examined the anti-tumor activity of IPI-926 following
cessation of T/C treatment. For these analyses, those mice
receiving either T/C alone or in combination with IPI-926 were
administered their third and final weekly dose of T/C on day 14 of
the treatment regimen (dotted line, Figure 4). The animals were
then maintained on either vehicle (T/C alone treated cohort) or
IPI-926 (T/C+IPI-926 treated cohort) and tumor volumes were
assessed at regular intervals. As shown in Figures 4A, 4B and 4C,
continued administration of IPI-926 following completion of T/C
treatment maintained tumor regression, and in one case (SOC13,
Figure 4B), resulted in a further decrease in tumor volume to levels
that were virtually undetectable. In contrast, we observed steadily
Figure 3. Cyclopamine alone impedes ovarian tumor growth.
Mice bearing human papillary serous ovarian tumor xenografts from
sample SOC11 were randomized into 2 cohorts with matched tumor
volumes and treated with either vehicle or cyclopamine. Tumor
volumes were assessed regularly. Change in tumor volume is shown
relative to the tumor volume at the beginning of the experiment. Error
bars represent the standard error of the mean (S.E.M). The significance
was determined using a Wilcoxon rank sum test.
doi:10.1371/journal.pone.0028077.g003
Figure 4. IPI-926 is an effective maintenance therapy. Mice
bearing tumors derived from patients diagnosed with serous ovarian
cancer were randomized into 4 cohorts (n=4–6 animals per treatment
cohort) with matched tumor volumes and subjected to the indicated
treatment regimens. Three independent papillary serous ovarian cancer
samples, SOC12 (A), SOC13 (B) and SOC14 (C) were used as biological
replicates. Cohorts were initially treated with vehicle alone (Control),
paclitaxel and carboplatinum (T/C) alone, IPI-926 alone or T/C+IPI-926 as
indicated. The last T/C dose was delivered on day 14 (indicated by the
dotted line). Percent change in tumor volume represents the change in
tumor volume relative to the tumor volume at the beginning of the
experiment. Error bars represent the standard error of the mean (S.E.M).
Significance was determined using a Wilcoxon rank sum test.
doi:10.1371/journal.pone.0028077.g004
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cessation of T/C administration. Thus, continued IPI-926
treatment resulted in a significant (p,0.02) difference in tumor
volume relative to that observed in vehicle treated mice for all
three individual primary tumors.
IPI-926 inhibits Hh pathway activity in both the stroma
and tumor
Recent data have suggested that Hh signaling in the stroma is
required for tumor development in mouse xenograft models of
pancreatic and colon cancer (25). To assess the site of action of
IPI-926 in our system, we analyzed Gli1 mRNA expression in both
mouse stroma and human tumor cells following either acute or
prolonged treatment with IPI-926. For the acute studies, mice
harboring xenografts generated from SOC12, SOC13 and
SOC14 were treated with either vehicle or IPI-926 for 24 hours.
Following tumor harvest, the relative expression of mouse and
human Gli1 was assessed by RT-PCR using species-specific
primers. The acute IPI-926 treatment led to a rapid significant
decrease in mouse Gli1 with no inhibition of human Gli1
expression (Figure 5, upper panel). We also analyzed stromal
and tumor specific Gli1 expression in the SOC12, SOC13 and
SOC14 xenografts harvested from the mice treated with either
vehicle or IPI-926 for 21 days in the studies shown in Figure 4.
Like in the acute setting, prolonged IPI-926 treatment led to a
significant inhibition of Gli1 mRNA expression in the stromal
(p,0.05) compartment (Figure 5, lower panel). In contrast to what
was also observed in the acute setting, moderate inhibition of Gli1
mRNA expression was observed in the tumor (p,0.03) following
prolonged treatment.
High Gli1 expression in the stroma of human papillary
serous ovarian tumors correlates with poor survival
In order to validate that Gli1 mRNA is expressed in the stroma
of human serous ovarian tumors, we examined the relative
expression of Gli1 in stroma microdissected from a second cohort
of 19 human primary ovarian serous tumors (Table S2). The
micro-dissected stroma of these tumors demonstrated a full range
of Gli1 mRNA expression (data not shown). Univariate survival
analysis revealed that high Gli1 mRNA expression in the stroma
correlated with a significantly worsened survival (Figure 6).
Discussion
Numerous investigators have documented the role of the Hh
signaling pathway in the development and maintenance of solid
tumors [4,6,7,8,9,10,11,12]. Recent evidence suggests that activa-
tion of this pathway is involved in the pathogenesis of ovarian
cancer (18, 20, 21). In our study, therapeutic targeting of this
pathway led to inhibition of human papillary serous tumor growth.
The Hh pathway inhibitor IPI-926 demonstrated significant anti-
tumor activity when administered as both a single agent and after
conventional cytotoxic therapy in primary tumor xenografts and
mediated its effects in both stromal and epithelial cells.
We initiated our investigation by analyzing the expression of
both the Hh pathway ligand Shh by immunohistochemistry and
Figure 5. IPI-926 blocks Hh pathway activity in mouse stromal and human tumor cells. Gli1 mRNA expression levels in xenograft tumors
derived from SOC12, SOC13, and SOC14 were analyzed by real time quantitative PCR following treatment of mice with IPI-926 for 24 hours (upper
panel) or 21 days (lower panel). The relative levels of human (left panel) and mouse (right panel) Gli1 mRNA expression were analyzed using species-
specific primers. Error bars represent the standard error of the mean (S.E.M). The significance (#p#0.03, *p=0.05, ** p#0.001) was determined using
Student’s t –test.
doi:10.1371/journal.pone.0028077.g005
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tumors. While some tumors, such as the majority of basal cell
carcinomas, have specific genetic defects that constitutively
activate the Hh pathway driving tumor growth, other solid tumors
appear to rely on increased levels of ligand to drive the Hh
signaling cascade [6,25]. Shh expression was previously reported
to be evident in a majority of ovarian cancer samples [18],
although this finding was disputed by Yang and colleagues [19]
who detected Shh expression in approximately 32% of samples.
We observed expression of Shh in 47% of the evaluated epithelial
ovarian malignancies. In contrast, Shh expression was absent in
benign ovarian tumors and less detectable in non-epithelial
ovarian malignancies. Our findings support previous work
suggesting that increased Hh pathway expression can contribute
to the pathogenesis of papillary serous ovarian carcinoma.
Upon activation of the Hh signaling pathway, the Gli1
transcription factor translocates to the nucleus and induces both
the expression of a number of genes involved in cell
proliferation and differentiation and its own transcription [26].
siRNA-mediated knockdown of Gli1 has been shown to reduce
cell proliferation rates [20]. Previous studies have reported
elevated Gli1 expression in ovarian cancer cell lines and
primary human ovarian tumor samples (18, 20). We analyzed
the level of Gli1 mRNA by real-time PCR in 10 individual
primary human papillary serous ovarian tumors and detected a
wide variability in expression. We also evaluated SHH, SMO,
Ptch1 and Gli1 expression in the 4 additional patient tumors used
to generate xenografts for our in vivo analyses. In each of these
tumors, Gli1 and SMO mRNA were expressed at a higher level
than either Ptch1 or SHH transcripts. Collectively, our results
suggest that the Hh signaling pathway may be active in a subset
of primary high grade serous ovarian tumors. Women whose
tumors manifest Hh pathway activation may be candidates for
potentially more effective targeted therapy directed against this
pathway.
Pre-clinical studies have reported that tumor growth was
significantly reduced in immunocompromised mice harboring
tumors generated from established ovarian cancer cell lines
following treatment with the naturally occurring Hh pathway
inhibitor cyclopamine [20]. In this study, we utilized primary
papillary serous ovarian carcinoma cells from multiple patients to
generate xenograft tumors in NOD/SCID mice and evaluate the
effect of Hh pathway inhibition on tumor growth. In our model,
cyclopamine demonstrated significant single agent activity. To
extend these findings, we carried out similar analyses using the
semi-synthetic cyclopamine derivative IPI-926 with increased
potency against the target (22). Like cyclopamine, IPI-926
demonstrated anti-tumor activity against two of the three analyzed
human papillary serous ovarian tumor xenografts when adminis-
tered as a single agent. Combined IPI-926 and T/C treatment
demonstrated no enhanced anti-tumor activity than treatment
with T/C alone. To assess the therapeutic potential of IPI-926
further, we evaluated its efficacy as a maintenance therapy. In
these analyses, T/C treatment was stopped after administration of
three doses, and the effect of continued IPI-926 treatment relative
to vehicle control treatment on tumor growth was evaluated. As
expected, the removal of T/C resulted in tumor re-growth in the
presence of vehicle. In contrast, continued IPI-926 treatment
inhibited ovarian tumor resurgence in all of the analyzed
xenografts following the completion of conventional cytotoxic
chemotherapy.
Previous studies have determined that Hh pathway inhibition of
tumor growth in pancreatic and colon carcinoma xenografts
models blocks paracrine signaling between the stroma and tumor
[27]. We examined the effect of acute and prolonged IPI-926
treatment on stromal and tumor Gli1 expression in our ovarian
xenograft model. Our results show that Gli1 expression in the
stroma was specifically and significantly reduced within 24 hours
of IPI-926 treatment while expression of Gli1 in tumor cells was
unaffected. However, prolonged (21 days) IPI-926 treatment
resulted in significant decreases in both stromal and tumor Gli1
expression. These data suggest prolonged inhibition of stromal Hh
signaling could ultimately lead to decreased Hh signaling in tumor
cells. Though the stromal compartment in this model is murine,
the Gli1 mRNA expression data from the microdissected stroma of
human serous ovarian cancer confirms that the Hh pathway is
active in human ovarian stroma, and that the degree of activation
may be of prognostic value. In this cohort, those with elevated Gli1
mRNA levels had worse overall survival, suggesting that targeting
the Hh cascade would be of greatest benefit to those who require
meaningful intervention.
In conclusion, our study suggests that the Hh pathway has a
role in the pathogenesis of papillary serous ovarian cancer that
may be mediated by both stromal and intra-tumor Gli1 levels.
IPI-926 demonstrated anti-tumor activity as both a single agent
and as a maintenance therapy after conventional cytotoxic
therapy in our human ovarian cancer xenograft models. Though
further investigation will be required to determine precisely how
Hh inhibition exerts this significant anti-neoplastic effect, our
data indicate that therapies for ovarian cancer directed against
the Hh cascade hold promise and merit exploration in clinical
trials.
Supporting Information
Figure S1 Change in percent weight over the course of
single agent cyclopamine therapy. No statistical difference in
weight was observed among the animals treated with cyclopamine
and vehicle.
(TIF)
Figure S2 Change in percent weight over the course of
treatment with IPI-926 and paclitaxel/carboplatinum
Figure 6. Stromal levels of Gli1 mRNA correlate with survival.
Survival analysis data obtained for Gli1 mRNA expression on
microdissected stroma samples of 19 patients using qRT-PCR validation.
Higher Gli1 mRNA expression correlated with decreased survival (Log-
rank Test, p,0.015) with a median survival of 26.50 months for patients
with low Gli1 mRNA expression versus 16 months for the patients that
had tumors with higher Gli1 mRNA expression in stroma.
doi:10.1371/journal.pone.0028077.g006
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statistically different from control in 2 of the 3 experiments (A and
C). No differences in weight were observed between vehicle and
IPI-926 alone treated animals in all experiments.
(TIF)
Table S1 Table summarizing clinical characteristics of
the 14 patients whose serous ovarian cancer specimens
were prospectively collected.
(PPT)
Table S2 Table summarizing the survival characteris-
tics of the 19 patient cohort with micro-dissected serous
ovarian tumors.
(DOC)
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